Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRQR Stock Forecast 2025-2026
$1.61
Current Price
$169.39M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRQR Price Targets
+831.7%
To High Target of $15.00
+490.1%
To Median Target of $9.50
+148.4%
To Low Target of $4.00
PRQR Price Momentum
-10.6%
1 Week Change
+43.8%
1 Month Change
-18.7%
1 Year Change
-39.2%
Year-to-Date Change
-65.2%
From 52W High of $4.62
+50.5%
From 52W Low of $1.07
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching ProQR (PRQR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PRQR and similar high-potential opportunities.
Latest PRQR Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, PRQR has a bullish consensus with a median price target of $9.50 (ranging from $4.00 to $15.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $1.61, the median forecast implies a 490.1% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Keay Nakae at Chardan Capital, suggesting a 148.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRQR Analyst Ratings
8
Buy
0
Hold
0
Sell
PRQR Price Target Range
Low
$4.00
Average
$9.50
High
$15.00
Current: $1.61
Latest PRQR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRQR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Initiates | $5.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $12.00 |
| Mar 14, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| Feb 12, 2025 | Jones Trading | Catherine Novack | Buy | Initiates | $11.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $10.00 |
| Dec 12, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Dec 12, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $10.00 |
| Oct 29, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Upgrade | $14.00 |
| May 10, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $5.00 |
| May 10, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.50 |
| Apr 18, 2024 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $2.00 |
| Mar 14, 2024 | HC Wainwright& Co. | Buy | Reiterates | $0.00 | |
| Mar 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $5.00 |
| Mar 14, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.50 |
| Nov 8, 2023 | Chardan Capital | Keay Nakae | Buy | Upgrade | $2.00 |
| Nov 8, 2023 | Raymond James | Steven Seedhouse | Outperform | Maintains | $4.00 |
| Sep 18, 2023 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $1.80 |
| Aug 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Aug 4, 2023 | Chardan Capital | Neutral | Reiterates | $0.00 |
ProQR Therapeutics N.V. (PRQR) Competitors
The following stocks are similar to ProQR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProQR Therapeutics N.V. (PRQR) Financial Data
ProQR Therapeutics N.V. has a market capitalization of $169.39M with a P/E ratio of 0.0x. The company generates $21.98M in trailing twelve-month revenue with a -142.0% profit margin.
Revenue growth is +35.3% quarter-over-quarter, while maintaining an operating margin of -226.9% and return on equity of -42.7%.
Valuation Metrics
Market Cap
$169.39M
Enterprise Value
$34.73M
P/E Ratio
0.0x
PEG Ratio
-3.4x
Price/Sales
8.7x
Growth & Margins
Revenue Growth (YoY)
+35.3%
Gross Margin
N/A
Operating Margin
-226.9%
Net Margin
-142.0%
EPS Growth
+31.2%
Financial Health
Cash/Price Ratio
+88.2%
Current Ratio
4.0x
Debt/Equity
19.4x
ROE
-42.7%
ROA
-12.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
ProQR Therapeutics N.V. (PRQR) Business Model
About ProQR Therapeutics N.V.
What They Do
Develops RNA-based therapies for genetic disorders.
Business Model
The company focuses on developing innovative RNA-editing therapies for genetic conditions, particularly genetic eye diseases and other rare disorders. ProQR generates revenue primarily through partnerships, collaborations, and potential future product sales once its therapies gain regulatory approval.
Additional Information
Founded in 2012 and based in the Netherlands, ProQR is recognized for its commitment to genetic research and innovation. Its work in RNA therapy reflects a growing trend in biopharmaceuticals, emphasizing the significance of addressing unmet medical needs in biotechnology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
156
CEO
Mr. Daniel Anton de Boer
Country
Netherlands
IPO Year
2014
Website
www.proqr.comProQR Therapeutics N.V. (PRQR) Latest News & Analysis
Latest News
Quick Summary
ProQR Therapeutics (Nasdaq: PRQR) reported Q1 2025 financial results and a business update, focusing on its RNA editing technology platform, Axiomer.
Why It Matters
ProQR Therapeutics' Q1 results and updates on its Axiomer RNA editing platform could impact stock performance and investor sentiment based on growth potential and innovation in RNA therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics (Nasdaq: PRQR) will present at the Citizens (JMP) Life Sciences Conference in NYC on May 8, 2025, at 11:30 AM EDT, showcasing its Axiomer™ RNA editing technology.
Why It Matters
ProQR's presentation at a prominent conference highlights its RNA therapies and technology, potentially attracting investor interest and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics N.V. announced developments in Leiden, Netherlands, and Cambridge, Mass., on May 1, 2025. Further details were not provided in the excerpt.
Why It Matters
ProQR Therapeutics’ announcement could indicate advancements in biotech, impacting stock performance and investment opportunities in gene therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
28 days ago
Quick Summary
ProQR Therapeutics NV, based in Leiden and Cambridge, announced news on April 14, 2025. Further details on the announcement were not provided in the excerpt.
Why It Matters
ProQR Therapeutics' announcement may signal developments in biotechnology, impacting stock performance and investment strategies in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR (PRQR) reported a quarterly loss of $0.10 per share, worse than the expected loss of $0.07, and higher than the loss of $0.08 per share from the previous year.
Why It Matters
ProQR's larger-than-expected quarterly loss signals potential operational issues and growth challenges, which could negatively impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
ProQR Therapeutics reported its financial results for 2024, highlighting its focus on RNA therapies using Axiomer RNA editing technology.
Why It Matters
ProQR's financial results and updates on its Axiomer RNA editing platform could signal growth potential, impacting stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRQR Stock
What is ProQR Therapeutics N.V.'s (PRQR) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, ProQR Therapeutics N.V. (PRQR) has a median price target of $9.50. The highest price target is $15.00 and the lowest is $4.00.
Is PRQR stock a good investment in 2025?
According to current analyst ratings, PRQR has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRQR stock?
Wall Street analysts predict PRQR stock could reach $9.50 in the next 12 months. This represents a 490.1% increase from the current price of $1.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProQR Therapeutics N.V.'s business model?
The company focuses on developing innovative RNA-editing therapies for genetic conditions, particularly genetic eye diseases and other rare disorders. ProQR generates revenue primarily through partnerships, collaborations, and potential future product sales once its therapies gain regulatory approval.
What is the highest forecasted price for PRQR ProQR Therapeutics N.V.?
The highest price target for PRQR is $15.00 from at , which represents a 831.7% increase from the current price of $1.61.
What is the lowest forecasted price for PRQR ProQR Therapeutics N.V.?
The lowest price target for PRQR is $4.00 from Keay Nakae at Chardan Capital, which represents a 148.4% increase from the current price of $1.61.
What is the overall PRQR consensus from analysts for ProQR Therapeutics N.V.?
The overall analyst consensus for PRQR is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.50.
How accurate are PRQR stock price projections?
Stock price projections, including those for ProQR Therapeutics N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 11:40 AM UTC